Abstract:Various stresses, including pressure overload and myocardial stretch, can trigger cardiac remodeling and result in heart diseases. The disorders are associated with high risk of morbidity and mortality and are among the major health problems in the world. MicroRNAs, a class of ~22nt-long small non-coding RNAs, have been found to participate in regulating heart development and function. One of them, miR-208a, a cardiac-specific microRNA, plays key role(s) in modulating gene expression in the heart, and is involved in a broad array of processes in cardiac pathogenesis. Genetic deletion or pharmacological inhibition of miR-208a in rodents attenuated stress-induced cardiac hypertrophy and remodeling. Transgenic expression of miR-208a in the heart was sufficient to cause hypertrophic growth of cardiomyocytes. miR-208a is also a key regulator of cardiac conduction system, either deletion or transgenic expression of miR-208a disturbed heart electrophysiology and could induce arrhythmias. In addition, miR-208a appeared to assist in regulating the expression of fast- and slow-twitch myofiber genes in the heart. Notably, this heart-specific miRNA could also modulate the “endocrine” function of cardiac muscle and govern the systemic energy homeostasis in the whole body. Despite of the critical roles, the underlying regulatory networks involving miR-208a are still elusive. Here, we summarize the progress made in understanding the function and mechanisms of this important miRNA in the heart, and propose several topics to be resolved as well as the hypothetical answers. We speculate that miR-208a may play diverse and even opposite roles by being involved in distinct molecular networks depending on the contexts. A deeper understanding of the precise mechanisms of its action under the conditions of cardiac homeostasis and diseases is needed. The clinical implications of miR-208a are also discussed.

MiR‐26a‐5p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

MiR-125b Inhibits Cardiomyocyte Apoptosis by Targeting BAK1 in Heart Failure.

Overexpression of Microrna-26B Attenuates Angiotensin II-induced Cardiac Hypertrophy Through Inhibition of Autophagic Responses.

MiR-26a-5p inhibits GSK3β expression and promotes cardiac hypertrophy in vitro

Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a

mir15a/mir16‐1 cluster and its novel targeting molecules negatively regulate cardiac hypertrophy

MicroRNA miR-27a-3p accelerates cardiac hypertrophy by targeting neuro-oncological ventral antigen 1

MiR-27a-3p/Hoxa10 Axis Regulates Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting Kv4.3 Expression

The molecular mechanism of MiR-26a-5p regulates autophagy and activates NLRP3 inflammasome to mediate cardiomyocyte hypertrophy

MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress.

Mir‐29a Attenuates Cardiac Hypertrophy Through Inhibition of PPARδ Expression

MiR-378 Inhibits Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting AKT2

Mir-154-5p Functions As an Important Regulator of Angiotensin II-Mediated Heart Remodeling.

MicroRNA-27 attenuates pressure overload-Induced cardiac hypertrophy and dysfunction by targeting galectin-3

Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy.

miR-208a in Cardiac Hypertrophy and Remodeling

ADAM17 knockdown mitigates while ADAM17 overexpression aggravates cardiac fibrosis and dysfunction via regulating ACE2 shedding and myofibroblast transformation

Overexpression of Microrna-99a Attenuates Cardiac Hypertrophy

Microrna363-5p targets thrombospondin3 to regulate pathological cardiac remodeling

miR‐31‐5p suppresses myocardial hypertrophy by targeting Nfatc2ip